The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus on Aspergillus spp.

Anna Rozaliyani; Budhi Antariksa; Fariz Nurwidya; Jamal Zaini; Findra Setianingrum; Firman Hasan; Husna Nugrahapraja; Humaira Yusva; Heri Wibowo; Anom Bowolaksono; Chris Kosmidis

doi:10.3390/life13041017

The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus on Aspergillus spp.

Anna Rozaliyani^*, Budhi Antariksa, Fariz Nurwidya, Jamal Zaini, Findra Setianingrum, Firman Hasan, Husna Nugrahapraja, Humaira Yusva, Heri Wibowo, Anom Bowolaksono, Chris Kosmidis

^*Corresponding author for this work

Division of Evolution, Infection and Genomics

Research output: Contribution to journal › Article › peer-review

Abstract

The heterogeneity of the lung microbiome and its alteration are prevalently seen among chronic lung diseases patients. However, studies to date have primarily focused on the bacterial microbiome in the lung rather than fungal composition, which might play an essential role in the mechanisms of several chronic lung diseases. It is now well established that Aspergillus spp. colonies may induce various unfavorable inflammatory responses. Furthermore, bacterial microbiomes such as Pseudomonas aeruginosa provide several mechanisms that inhibit or stimulate Aspergillus spp. life cycles. In this review, we highlighted fungal and bacterial microbiome interactions in the respiratory tract, with a focus on Aspergillus spp.

Original language	English
Article number	1017
Journal	Life
Volume	13
Issue number	4
DOIs	https://doi.org/10.3390/life13041017
Publication status	Published - 14 Apr 2023

Keywords

Aspergillusspp
chronic lung diseases
immunological response
lung mycobiome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/life13041017Licence: CC BY

Cite this

@article{c0495a45848a4bf1a1a2d13b20bb2eed,

title = "The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus on Aspergillus spp.",

abstract = "The heterogeneity of the lung microbiome and its alteration are prevalently seen among chronic lung diseases patients. However, studies to date have primarily focused on the bacterial microbiome in the lung rather than fungal composition, which might play an essential role in the mechanisms of several chronic lung diseases. It is now well established that Aspergillus spp. colonies may induce various unfavorable inflammatory responses. Furthermore, bacterial microbiomes such as Pseudomonas aeruginosa provide several mechanisms that inhibit or stimulate Aspergillus spp. life cycles. In this review, we highlighted fungal and bacterial microbiome interactions in the respiratory tract, with a focus on Aspergillus spp.",

keywords = "Aspergillusspp, chronic lung diseases, immunological response, lung mycobiome",

author = "Anna Rozaliyani and Budhi Antariksa and Fariz Nurwidya and Jamal Zaini and Findra Setianingrum and Firman Hasan and Husna Nugrahapraja and Humaira Yusva and Heri Wibowo and Anom Bowolaksono and Chris Kosmidis",

note = "Funding Information: This research was partly funded by Kemenristek/BRIN with a grant number NKB-2883/UN2.RST/HKP.05.00/2020. Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = apr,

day = "14",

doi = "10.3390/life13041017",

language = "English",

volume = "13",

journal = "Life",

issn = "2075-1729",

publisher = "MDPI",

number = "4",

}

TY - JOUR

T1 - The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus on Aspergillus spp.

AU - Rozaliyani, Anna

AU - Antariksa, Budhi

AU - Nurwidya, Fariz

AU - Zaini, Jamal

AU - Setianingrum, Findra

AU - Hasan, Firman

AU - Nugrahapraja, Husna

AU - Yusva, Humaira

AU - Wibowo, Heri

AU - Bowolaksono, Anom

AU - Kosmidis, Chris

PY - 2023/4/14

Y1 - 2023/4/14

N2 - The heterogeneity of the lung microbiome and its alteration are prevalently seen among chronic lung diseases patients. However, studies to date have primarily focused on the bacterial microbiome in the lung rather than fungal composition, which might play an essential role in the mechanisms of several chronic lung diseases. It is now well established that Aspergillus spp. colonies may induce various unfavorable inflammatory responses. Furthermore, bacterial microbiomes such as Pseudomonas aeruginosa provide several mechanisms that inhibit or stimulate Aspergillus spp. life cycles. In this review, we highlighted fungal and bacterial microbiome interactions in the respiratory tract, with a focus on Aspergillus spp.

AB - The heterogeneity of the lung microbiome and its alteration are prevalently seen among chronic lung diseases patients. However, studies to date have primarily focused on the bacterial microbiome in the lung rather than fungal composition, which might play an essential role in the mechanisms of several chronic lung diseases. It is now well established that Aspergillus spp. colonies may induce various unfavorable inflammatory responses. Furthermore, bacterial microbiomes such as Pseudomonas aeruginosa provide several mechanisms that inhibit or stimulate Aspergillus spp. life cycles. In this review, we highlighted fungal and bacterial microbiome interactions in the respiratory tract, with a focus on Aspergillus spp.

KW - Aspergillusspp

KW - chronic lung diseases

KW - immunological response

KW - lung mycobiome

UR - http://www.scopus.com/inward/record.url?scp=85156101162&partnerID=8YFLogxK

U2 - 10.3390/life13041017

DO - 10.3390/life13041017

M3 - Article

C2 - 37109545

AN - SCOPUS:85156101162

SN - 2075-1729

VL - 13

JO - Life

JF - Life

IS - 4

M1 - 1017

ER -

The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus on Aspergillus spp.

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

MFIG: Manchester Fungal Infection Group (MFIG)

Cite this

The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus on Aspergillus spp.

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

MFIG: Manchester Fungal Infection Group (MFIG)

Cite this